Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John D Davis

Showing results (61-70 of 88) with videos related to

Pageof 9
Sort By:
Clinical Pharmacology in Drug Development|April 30, 2020
Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Dupilumab in Healthy Adult SubjectsZhaoyang Li, Allen Radin, Meng Li, et al.
Journal of Drugs in Dermatology : JDD|August 20, 2019
Efficacy of Dupilumab in Different Racial Subgroups of Adults With Moderate-to-Severe Atopic Dermatitis in Three Randomized, Placebo-Controlled Phase 3 TrialsAndrew F. Alexis, Marta Rendon, Jonathan I. Silverberg, et al.
Clinical and Translational Science|July 30, 2024
Pharmacokinetics and pharmacodynamics of itepekimab in adults with moderate-to-severe atopic dermatitis: Results from two terminated phase II trialsMatthew P Kosloski, Emma Guttman-Yassky, Michael J Cork, et al.
Dermatology and Therapy|April 29, 2026
Summary of Research: Immunogenicity of Dupilumab in Adult and Pediatric Patients with Atopic DermatitisMatthew P Kosloski, Ching-Ha Lai, Michael A Partridge, et al.
Pharmaceutical Research|December 11, 2023
Integrated Exposure-Response of Dupilumab in Children, Adolescents, and Adults With Atopic Dermatitis Using Categorical and Continuous Efficacy Assessments: A Population AnalysisEmily Briggs, Mohamed A Kamal, Matthew P Kosloski, et al.
Clinical Pharmacology and Therapeutics|July 16, 2021
The Posology of Dupilumab in Pediatric Patients With Atopic DermatitisMohamed A Kamal, Pavel Kovalenko, Matthew P Kosloski, et al.
Osteoarthritis and Cartilage Open|November 18, 2024
A phase III study to evaluate the long-term safety and efficacy of fasinumab in patients with pain due to osteoarthritis of the knee or hipStephen J DiMartino, Jingning Mei, Thomas J Schnitzer, et al.
BMC Musculoskeletal Disorders|February 25, 2025
Efficacy and safety of fasinumab in an NSAID-controlled study in patients with pain due to osteoarthritis of the knee or hipStephen J DiMartino, Haitao Gao, Simon Eng, et al.
Nature Communications|May 13, 2025
GDF8 and activin A are the key negative regulators of muscle mass in postmenopausal females: a randomized phase I trialDinko Gonzalez Trotter, Stephen Donahue, Chris Wynne, et al.
CPT: Pharmacometrics & Systems Pharmacology|March 17, 2025
Comparison of Model-Predicted and Observed Evinacumab Pharmacokinetics and Efficacy in Children Aged < 5 Years With Homozygous Familial HypercholesterolemiaSébastien Bihorel, Robert Dingman, Jeanne Mendell, et al.
Pageof 9

Showing results (61-70 of 88) with videos related to

Sort By:
Pageof 9
Clinical Pharmacology in Drug Development|April 30, 2020
Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Dupilumab in Healthy Adult SubjectsZhaoyang Li, Allen Radin, Meng Li, et al.
Journal of Drugs in Dermatology : JDD|August 20, 2019
Efficacy of Dupilumab in Different Racial Subgroups of Adults With Moderate-to-Severe Atopic Dermatitis in Three Randomized, Placebo-Controlled Phase 3 TrialsAndrew F. Alexis, Marta Rendon, Jonathan I. Silverberg, et al.
Clinical and Translational Science|July 30, 2024
Pharmacokinetics and pharmacodynamics of itepekimab in adults with moderate-to-severe atopic dermatitis: Results from two terminated phase II trialsMatthew P Kosloski, Emma Guttman-Yassky, Michael J Cork, et al.
Dermatology and Therapy|April 29, 2026
Summary of Research: Immunogenicity of Dupilumab in Adult and Pediatric Patients with Atopic DermatitisMatthew P Kosloski, Ching-Ha Lai, Michael A Partridge, et al.
Pharmaceutical Research|December 11, 2023
Integrated Exposure-Response of Dupilumab in Children, Adolescents, and Adults With Atopic Dermatitis Using Categorical and Continuous Efficacy Assessments: A Population AnalysisEmily Briggs, Mohamed A Kamal, Matthew P Kosloski, et al.
Clinical Pharmacology and Therapeutics|July 16, 2021
The Posology of Dupilumab in Pediatric Patients With Atopic DermatitisMohamed A Kamal, Pavel Kovalenko, Matthew P Kosloski, et al.
Osteoarthritis and Cartilage Open|November 18, 2024
A phase III study to evaluate the long-term safety and efficacy of fasinumab in patients with pain due to osteoarthritis of the knee or hipStephen J DiMartino, Jingning Mei, Thomas J Schnitzer, et al.
BMC Musculoskeletal Disorders|February 25, 2025
Efficacy and safety of fasinumab in an NSAID-controlled study in patients with pain due to osteoarthritis of the knee or hipStephen J DiMartino, Haitao Gao, Simon Eng, et al.
Nature Communications|May 13, 2025
GDF8 and activin A are the key negative regulators of muscle mass in postmenopausal females: a randomized phase I trialDinko Gonzalez Trotter, Stephen Donahue, Chris Wynne, et al.
CPT: Pharmacometrics & Systems Pharmacology|March 17, 2025
Comparison of Model-Predicted and Observed Evinacumab Pharmacokinetics and Efficacy in Children Aged < 5 Years With Homozygous Familial HypercholesterolemiaSébastien Bihorel, Robert Dingman, Jeanne Mendell, et al.
Pageof 9